Welcome to our dedicated page for Arkema news (Ticker: ARKAY), a resource for investors and traders seeking the latest updates and insights on Arkema stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arkema's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arkema's position in the market.
Arkema has executed share buyback transactions from October 10 to October 14, 2022, totaling 15,000 shares. The weighted average price of these acquisitions stands at €74.6016 per share. The operations are conducted in compliance with EU regulations, specifically Article 5 §2 of Regulation (EU) No 596/2014. These transactions aim to enhance shareholder value by reducing the number of shares outstanding, which could potentially lead to an increase in earnings per share.
Arkema has announced share buyback transactions from October 3 to October 7, 2022, in accordance with EU regulations. A total of 35,000 shares were repurchased at an average price of €77.0375 per share. Specific daily figures include 7,000 shares bought each day, with prices ranging from €75.2278 to €79.0034. This buyback program may positively affect shareholder value and signal confidence in the company's future performance.
On September 30, 2022, Arkema reported a total of 74,286,041 shares and 88,819,279 voting rights, including those held by the company. The total number of voting rights, excluding the shares held by the company, was 88,402,284. This disclosure is in compliance with regulatory requirements on share and voting rights updates.
Arkema has announced an expansion of its Pebax® elastomer capacity at the Serquigny site in France, increasing global production by 40%. This expansion consists of two phases, with a 15% increase in Q1 2023 and an additional 25% starting in Q3 2023. The increase caters to strong demand from sectors such as sports, consumer electronics, and medical markets, particularly for its bio-based Pebax® Rnew® grades. Additionally, Arkema aims to reduce water consumption at the Serquigny site by 25% through improved processes.
Arkema (Euronext: AKE) announced share buyback transactions conducted from September 12 to September 16, 2022, totaling 1,083 shares. The weighted average acquisition price was €87.7581 per share. These actions align with Article 5 §2 of Regulation (EU) No 596/2014, aimed at enhancing shareholder value by reducing the number of outstanding shares. Further details can be accessed on Arkema's investor relations webpage.
Arkema is initiating a capital increase for current and former employees in 30 countries, including France, from 16 September 2022 to 29 September 2022. The maximum nominal amount is €13.5 million, and shares will be priced at €64.35, which is 75% of the average share price over the previous 20 trading days. The maximum number of shares issued will be 1.35 million. This initiative aims to strengthen employee ties to the company’s performance and future developments.
Arkema has disclosed its share buyback transactions from September 5 to September 9, 2022, on the Euronext Paris exchange. During this period, Arkema repurchased a total of 35,000 shares at a weighted average price of €83.4386 per share. The transactions are in alignment with Article 5 §2 of Regulation (EU) No 596/2014. The buyback details are part of the company's effort to enhance shareholder value and can be accessed on their investor relations website.
Arkema announced share buyback transactions conducted from 29 August to 02 September 2022. A total of 13,917 shares were repurchased, with the weighted average purchase price being €84.2903. The transactions are authorized under Regulation (EU) No 596/2014. These buybacks reflect Arkema's commitment to enhance shareholder value and return capital.
On 1 September 2022, Arkema finalized the acquisition of Polimeros Especiales, enhancing its offerings in solvent-free solutions. The Mexican company specializes in high-performance waterborne resins across various sectors, achieving sales of approximately US$40 million in 2021. This acquisition aims to strengthen Arkema’s position in high-growth markets and promote sustainable innovations. With a strategic focus on specialty materials, Arkema reported sales of around €9.5 billion in 2021, operating in 55 countries with 20,200 employees.
Arkema has announced share buyback transactions conducted from August 22 to August 26, 2022, in compliance with European regulations. A total of 28,137 shares were repurchased during this period. The daily trading volumes and weighted average prices for the shares each day are detailed, with the highest daily volume being 7,000 shares at a weighted average price of 86.3230 on August 23. The shares were purchased on the Euronext Paris exchange.